LTL-388 datasheet

Origin	Primary human uterus carcinoma	**Histopathology**	High grade serous carcinoma of endometrium
Year of establishment	2010	**Doubling time**	7.5 days (sub-renal capsule site)
Local invasion	No	**Metastasis**	No

The LTL-388 (Figure 1) was developed from a patient's primary serous carcinoma of the uterus (Figure 2). When grafted under the renal capsules of SCID mice, the LTL-388 shows no local invasion into adjacent host kidney parenchyma and no metastasis to distant organs.



Fig 1. H&E stained LTL-388 tissue sections.

Showing the LTL-388 cells form glandular or abortive glandular structure and contain prominent nucleoli. (x200)



Fig 2. The patient's cancer tissue before grafting.

The highly pleomorphic tumor cells grow in glandular patterns and contain highly prominent nucleoli.

Genetic and epigenetic characteristics

Tissue microarrays containing LTL-388 tissue are available for screening potential molecular targets.

Applications

1. Pre-clinical evaluation of existing and potential anticancer drugs. Examination of drug efficacy on tumor growth, cell death (apoptosis, necrosis), and angiogenesis.

2. Discovery of potential therapeutic and/or biomarkers for drug sensitivity targets.

3. Study of mechanisms underlying tumor growth and progression.

References

1. Lee et al., Gynecologic Oncology 2005; 96: 48-55

2. Press et al., Gynecologic Oncology 2008; 110: 256-264

For more information, please contact us by email: LTL@bccrc.ca or phone: (604) 675 8013